Genomic Valley Biotech Ltd

Fintellectual Corporate Advisors Pvt Ltd, acting as the Manager to the Open Offer, has submitted a Public Announcement regarding an open offer for the acquisition of up to 7,94,170 equity shares of Genomic Valley Biotech Limited (GVBL). The offer represents 26.00% of the voting share capital. The acquirers, Mr. Pankaj Grover and Mr. Abhisek Gupta, are offering ₹30 per equity share. This open offer is being made pursuant to SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The total value of the offer, based on the maximum number of shares, is approximately ₹23.82 Crore.

Genomic Valley Biotech Ltd has announced the closure of its trading window effective October 1, 2026, in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. This closure is to facilitate the consideration of the un-audited financial results for the quarter and half-year ended September 30, 2026. The trading window will reopen 48 hours after the announcement of these results. During this period, directors, key managerial personnel, designated persons, and their immediate relatives are prohibited from trading in the company's shares and securities. The date for the board meeting to approve these financial results will be communicated separately.

Genomic Valley Biotech Ltd has received approval from the Registrar of Companies, Haryana, for a three-month extension to hold its Annual General Meeting (AGM) for the financial year ended March 31, 2026. The AGM, originally due by September 30, 2026, can now be held until December 31, 2026. The extension was granted on grounds of promoter health reasons. The company was advised to ensure future compliance with the Companies Act, 2013.

Genomic Valley Biotech Ltd announced its unaudited financial results for the quarter ended June 30, 2026. The Board of Directors approved the standalone financial results during a meeting held on August 14, 2026. A limited review report from the statutory auditor is enclosed with the results. The company has prepared these results in accordance with Indian Accounting Standards.

Genomic Valley Biotech Ltd announced that its Board of Directors has considered and approved the standalone un-audited financial results for the quarter ended June 30, 2026. The board meeting took place on August 14, 2026. A limited review report from the statutory auditor is enclosed with the results. The company's registered office is located in Haryana, and the corporate office is in Delhi.

Genomic Valley Biotech Ltd has announced that its Board of Directors will convene on August 14, 2026. The primary agenda item is to consider and approve the unaudited financial results for the quarter ending June 30, 2026. Additionally, the meeting will address any other business as permitted by the chairman. In compliance with SEBI regulations, the trading window for company securities will be closed from July 1, 2026, until 48 hours after the results are publicly disclosed, affecting directors, KMPs, promoters, and designated persons.

Genomic Valley Biotech Ltd has announced the closure of its trading window effective July 1, 2026, in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. This closure is to facilitate the consideration of the un-audited financial results for the quarter ended June 30, 2026. The trading window will reopen 48 hours after the announcement of these results. During this period, designated persons, including employees, directors, and their immediate relatives, are prohibited from trading in the company's shares and securities. The date for the board meeting to approve these financial results will be communicated separately.

Genomic Valley Biotech Ltd has appointed Mr. Navjyoti Kumar Jha as the internal auditor for the financial year 2026-27. The decision was made during a Board of Directors meeting held on May 29, 2026, where the board also approved the standalone audited financial results for the quarter and financial year ended March 31, 2026. Mr. Jha has 26 years of experience and is not related to any director of the company.

Genomic Valley Biotech Ltd's Board of Directors approved the standalone audited financial results for the quarter and financial year ended March 31, 2026. The board also approved the appointment of Mr. Navjyoti Kumar Jha as the Internal Auditor for the F.Y. 2026-27. The meeting commenced at 04:00 P.M. and concluded at 05:20 P.M.

Genomic Valley Biotech Ltd has scheduled a Board of Directors meeting on May 29, 2026, to consider and approve the audited financial results (standalone) for the quarter and year ended March 31, 2026. The trading window for dealing in the company's securities is closed from April 01, 2026, until 48 hours after the results are made public.